MRK (Merck & Co., Inc.) Expected net earnings per share growth this year

MRK (MSD) - company brandmark

Merck & Co., Inc. leads in cancer treatment through its exclusive drugs. The annual EPS trend demonstrates the current growth vector, where -69.10 represents the latest level. High certification and patent costs block competitor access. Proprietary medical protocols create a sustainable ecosystem that retains patients within the therapy.

MRK - Merck Earnings growth in current year over the range 07/04/2022 - 11/12/2026

Financial and market metric breakdowns for Merck & Co., Inc. (MRK)

- stock quotes and analyst forecast:
Share Price Merck & Co.|MRK - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization MSD|MRK - Total Company Value
- shareholders' equity book value data:
Equity per Share Merck|MRK - Book Capitalization|Market Value to Equity Ratio merck.com|MRK - Aggregate Company Assets
- debt and liquidity details:
Total Debt to Equity Ratio Merck & Co., Inc.|MRK - Long-Term Debt to Capital|Current Liabilities to Capital merck.com|MRK - Company Debts|Debt to Net Assets Ratio MSD|MRK - Company Long-Term Debts|Company Current Liabilities Merck|Quick Ratio merck.com
- earnings and market ratios statistics:
MRK - Net Income|Expected Net Income Merck & Co., Inc.|MRK - Price to Earnings Multiple|Market Cap to Future Earnings Ratio MSD|MRK - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation MSD|MRK - Operating profit EBITDA|Net earnings per share for the last 12 months Merck|MRK - Earnings per share for the last twelve months|Earnings per share growth in annualized terms for the last twelve months merck.com|MRK - Net earnings per share growth this year|Consensus forecast of earnings per share growth for next year Merck & Co., Inc.
Basic company analysis:Merck & Co. (MRK)
Core merchandise of Merck Sharp & Dohme

This indicator measures the percentage change in net earnings per share relative to the same period last year, allowing for an assessment of the business's scaling pace. By analyzing the annual EPS growth rate, an investor can gauge the efficiency of innovation monetization at Merck & Co., Inc. (MRK), confirming the company's status as an oncology leader with a high level of market confidence.

Direct competitors

Earnings per share growth this year LLY|ABBV (Abbvie) - Earnings growth in current year|AstraZeneca Corp. (AZN) - Expected net earnings per share growth this year|Earnings per share growth in current year Novartis AG (NVS)|novonordisk.com - Earnings per share growth this year|Earnings growth in current year AMGN (Amgen)|Net earnings per share change in current year Pfizer Inc|SNY - Earnings per share growth in current year|Bristol-Myers Squibb Co. (BMY) - Net earnings per share growth this year|GSK: Earnings growth in current year|Earnings per share growth rate in current year takeda.com (TAK)|Earnings per share growth in current year Teva Pharmaceuticals|RDY: Earnings per share increase in current year|Earnings growth in current year VTRS|Net earnings per share growth this year Roivant Corp ROIV|Earnings per share growth in current year Zai Lab Limited ZLAB|Earnings growth in current year bauschhealth.com BHC|COSM: Net earnings per share growth this year